Inorganic chemistry in nuclear imaging and radiotherapy: Current and future directions

Radiochimica Acta

Volumn 100, Issue 8-9, 2012, Pages 653-667

  Carroll, V ^a   Demoin, D W ^a   Hoffman, T J ^a,b,c   Jurisson, S S ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bifunctional chelates; Nuclear imaging; Radiometals; Radiotherapy; Specific targeting

Indexed keywords

EID: 84866358148     PISSN: 00338230     EISSN: None     Source Type: Journal    
DOI: 10.1524/ract.2012.1964     Document Type: Article

References (171)

1. Brucer, M., Harris, C. C., MacIntyre,W. J., Taplin, G. V. (eds.): The Heritage of Nuclear Medicine: Commemorating the 25th Anniversary of the Society of Nuclear Medicine, 1954-1979. Society of Nuclear Medicine, New York (1979), 166 pp
2. The Technetium-99m Generator in Brookhaven History by Brookhaven National Laboratories http://www.bnl.gov/bnlweb/history/tc-99m.asp (2010)
3. Mausner, L. F., Mirzadeh, S.: Reactor production of radionuclides. In: Handbook of Radiopharmaceuticals: Radiochemistry and Applications. (Welch, M. J. and Redvanly, C. S., eds.) John Wiley & Sons, Ltd, New York (2003), pp. 87-118
4. Ballinger, J. R.: 99Mo shortage in nuclear medicine: Crisis or challenge? J. Label. Compd. Radiopharm. 53, 167-168 (2010)
5. Bhattacharyya, S., Dixit, M.: Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals. Dalton Trans. 40, 6112-6128 (2011)
6. McQuade, P., Rowland, D. J., Lewis, J. S., Welch, M. J.: Positronemitting isotopes produced on biomedical cyclotrons. Curr. Med. Chem. 12, 807-818 (2005)
7. Ruth, T. J.: The uses of radiotracers in the life sciences. Rep. Progr. Phys. 72, 1-23 (2009)
8. Volkert,W. A., Goeckeler,W. F., Ehrhardt, G. J., Ketring, A. R.: Therapeutic radionuclides: Production and decay property considerations. J. Nucl. Med. 32, 174-185 (1991)
9. Welch, M. J., Redvanly, C. S. (eds.): Handbook of Radiopharmaceuticals: Radiochemistry and Applications. John Wiley & Sons Ltd, New York (2003), 848 pp
10. Qaim, S. M.: Cyclotron production of medical radionuclides. In: Radiochemistry and Radiopharmaceutical Chemistry in Life Sciences. 2nd Edn. (Vertes, A., Nagy, S., and Klencsar, Z., eds.) Kluwer Academic Publishers, Dordrecht/Boston/London (2003), pp. 47-79
11. Anderson, C. J., Welch, M. J.: Radiometal-labeled agents (nontechnetium) for diagnostic imaging. Chem. Rev. 99, 2219-2234 (1999)
12. Banerjee, S. R., Maresca, K. P., Francesconi, L., Valliant, J., Babich, J. W., Zubieta, J.: New directions in the coordination chemistry of99Tc: A reflection on technetium core structures and a strategy for new chelate design. Nucl. Med. Biol. 32, 1-20 (2005)
13. Blower, P.: Towards molecular imaging and treatment of disease with radionuclides: the role of inorganic chemistry. Dalton Trans 1705-1711 (2006)
14. Jurisson, S., Berning, D., Jia,W., Ma, D.: Coordination compounds in nuclear medicine. Chem. Rev. 93, 1137-1156 (1993)
15. Jurisson, S. S., Lydon, J. D.: Potential technetium small molecule radiopharmaceuticals. Chem. Rev. 99, 2205-2218 (1999)
16. Liu, S., Edwards, D. S.: 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem. Rev. 99, 2235-2268 (1999)
17. Reichert, D. E., Lewis, J. S., Anderson, C. J.: Metal complexes as diagnostic tools. Coord. Chem. Rev. 184, 3-66 (1999)
18. Schibli, R., Schubiger, A. P.: Current use and future potential of organometallic radiopharmaceuticals. Eur. J. Nucl. Med. 29, 1529-1542 (2002)
19. Schubiger, P. A., Alberto, R., Smith, A.: Vehicles, chelators, and radionuclides: Choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Bioconj. Chem. 7, X1-179 (1996)
20. Volkert,W. A., Hoffman, T. J.: Therapeutic radiopharmaceuticals. Chem. Rev. 99, 2269-2292 (1999)
21. Zeglis, B. M., Lewis, J. S.: A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. Dalton Trans. 40, 6168-6195 (2011)
22. Rey, A.M.: Radiometal complexes in molecular imaging and therapy. Curr. Med. Chem. 17, 3673-3683 (2010)
23. Gotthardt,M., Boermann, O. C., Behr, T. M., Behe, M. P., Oyen, W. J.: Development and clinical application of peptide-based radiopharmaceuticals. Curr. Med. Chem. 10, 2951-2963 (2004)
24. Maecke, H. R., Reubi, J. C.: Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J. Nucl. Med. 52, 841-844 (2011)
25. Qaim, S. M.: Development of novel positron emitters for medical applications:Nuclear and radiochemical aspects. Radiochim. Acta 99, 611-625 (2011)
26. National Nuclear Data Center, Brookhaven National Laboratory, last update: 12 January 2012, http://www.nndc.bnl.gov/
27. Liu, S.: Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv. Drug Deliv. Rev. 60, 1347-1370 (2008)
28. Chen, K., Conti, P. S.: Target-specific delivery of peptide-based probes for PET imaging. Adv. Drug Deliv. Rev. 62, 1005-1022 (2010)
29. Correia, J. D. G., Paulo, A., Raposinho, P. D., Santos, I.: Radiometallated peptides for molecular imaging and targeted therapy. Dalton Trans. 40, 6144-6167 (2011)
30. De León-Rodríguez, L. M., Kovacs, Z.: The synthesis and chelation chemistry of DOTA - peptide conjugates. Bioconj. Chem. 19, 391-402 (2008)
31. Goldenberg, D. M., Rossi, E. A., Sharkey, R. M., McBride,W. J., Chang, C. H.: Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting. J. Nucl. Med. 49, 158-163 (2008)
32. Okarvi, S. M.: Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancer. Cancer Treat. Rev. 34, 13-26 (2008)
33. Deutscher, S. L.: Phage display in molecular imaging and diagnosis of cancer. Chem. Rev. 110, 3196-3211 (2010)
34. Lee, S., Xie, J., Chen, X.: Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem. Rev. 110, 3087- 3111 (2010)
35. Lee, S., Xie, J., Chen, X.: Peptide-based probes for targeted molecular imaging. Biochemistry 49, 1364-1376 (2010)
36. Nanda, P. K., Lane, S. R., Retzloff, L. B., Pandey, U. S., Smith, C. J.: Radiolabeled regulatory peptides for imaging and therapy. Curr. Opin. Endocrinol. 17, 69-76 (2010)
37. Schottelius,M., Wester, H. J.: Molecular imaging targeting peptide receptors. Methods 48, 161-177 (2009)
38. Tweedle, M. F.: Peptide-targeted diagnostics and radiotherapeutics. Acc. Chem. Res. 42, 958-968 (2009)
39. Yan, Y., Chen, X.: Peptide heterodimers for molecular imaging. Amino Acids 1-12 (2010)
40. Wadas, T. J., Wong, E. H., Weisman, G. R., Anderson, C. J.: Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem. Rev 110, 2858-2902 (2010)
41. Cole, W. C., DeNardo, S. J., Meares, C. F., McCall, M. J., DeNardo, G. L., Epstein, A. L., O'Brien, H. A., Moi,M. K.: Comparative serum stability of radiochelates for antibody radiopharmaceuticals. J. Nucl. Med. 28, 83-90 (1987)
42. Moi,M. K., DeNardo, S. J., Meares, C. F.: Stable bifunctional chelates of metals used in radiotherapy. Cancer Res. 50, 789-793 (1990)
43. Davison, A.: The coordination chemistry of technetium. In: Technetium in Chemistry and Nuclear Medicine (Deutsch, E., Nicolini, M., Wagner, H. N., eds.) Cortina International, Verona (1983), pp. 3-14
44. Davison, A., Jones, A. G., Orvig, C., Sohn,M.: A new class of oxotechnetium(5+) chelate complexes containing a TcON2S2 core. Inorg. Chem. 20, 1629-1632 (1981)
45. Deutsch, E., Bushong,W., Glavan, K., Elder, R., Sodd, V., Scholz, K., Fortman, D., Lukes, S.: Heart imaging with cationic complexes of technetium. Science 214, 85-86 (1981)
46. Deutsch, E., Libson, K.: Application of technetium chemistry to the practice of nuclear medicine. In: Technetium in Chemistry and Nuclear Medicine. (Deutsch, E., Nicolini,M., Wagner,H. N., eds.) Cortina International, Verona (1983), pp. 29-36
47. Holman, B. L., Jones, A. G., Lister-James, J., Davison, A., Abrams, M. J., Kirshenbaum, J. M., Tumeh, S. S., English, R. J.: A new Tc-99m-labeled myocardial imaging agent, hexakis(t- Butylisonitrile)-technetium(I) [Tc-99m TBI]: Initial experience in the human. J. Nucl. Med. 25, 1350-1355 (1984)
48. Vanderheyden, J. L., Ketring,A. R., Libson, K., Heeg,M. J., Roecker, L., Motz, P., Whittle, R., Elder, R. C., Deutsch, E.: Synthesis and characterization of cationic technetium complexes of 1-2-bis(dimethylphosphino)ethane (DMPE). Structure determinations of trans-[TcV(DMPE)2(OH)(O)](F3CSO3)2, trans- [TcIII(DMPE)2Cl2]F3CSO3, and [TcI(DMPE)3]+ using X-ray diffraction, EXAFS, and technetium-99 NMR. Inorg. Chem. 23, 3184-3191 (1984)
49. Bartholoma,M., Valliant, J., Maresca, K. P., Babich, J., Zubieta, J.: Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals. Chem. Commun. 5, 493-512 (2009)
50. Tisato, F., Porchia,M., Bolzati, C., Refosco, F., Vittadini, A.: The preparation of substitution-inert 99Tc metal-fragments: Promising candidates for the design of new 99mTc radiopharmaceuticals. Coord. Chem. Rev. 250, 2034-2045 (2006)
51. Pasqualini, R., Duatti, A.: Synthesis and characterization of the new neutral myocardial imaging agent (99mTcN(NOET)2) (NOET = N-Ethyl-N- ethoxydithiocarbamato). Chem. Inform. 23, 1354-1355 (1992)
52. Pasqualini, R., Duatti, A., Bellande, E., Comazzi, V., Brucato, V., Hoffschir, D., Fagret, D., Comet, M.: Bis(Dithiocarbamato) nitrido technetium-99m radiopharmaceuticals: A class of neutral myocardial imaging agents. J. Nucl. Med. 35, 334-341 (1994)
53. Bolzati, C., Cavazza-Ceccato,M., Agostini, S., Tokunaga, S., Casara, D., Bandoli, G.: Subcellular distribution and metabolism studies of the potential myocardial imaging agent [99mTc(N)- (DBODC)(PNP5)]+. J. Nucl. Med. 49, 1336-1344 (2008)
54. Hatada, K., Riou, L. M., Ruiz, M., Yamamichi, Y., Duatti, A., Lima, R. L., Goode, A. R., Watson, D. D., Beller, G. A., Glover, D. K.: 99mTc-N-DBODC5, a new myocardial perfusion imaging agent with rapid liver clearance: Comparison with 99mTcsestamibi and 99mTc-tetrofosmin in rats. J. Nucl. Med. 45, 2095-2101 (2004)
55. Kim, Y.-S., Wang, J., Broisat, A., Glover, D. K., Liu, S.: Tc-99m- N-MPO: Novel cationic Tc-99m radiotracer for myocardial perfusion imaging. J. Nucl. Cardiol. 15, 535-546 (2008)
56. Liu, S.: Ether and crown ether-containing cationic 99mTc complexes useful as radiopharmaceuticals for heart imaging. Dalton Trans. 1183-1193 (2007)
57. Liu, Z., Chen, L., Liu, S., Barber, C., Stevenson, G., Furenlid, L., Barrett, H., Woolfenden, J.: Kinetic characterization of a novel cationic 99mTc(I)-tricarbonyl complex, 99mTc-15C5-pNP, for myocardial perfusion imaging. J. Nucl. Cardiol. 17, 858-867 (2010)
58. Mendes, F., Gano, L., Fernandes, C., Paulo, A., Santos, I.: Studies of the myocardial uptake and excretion mechanisms of a novel 99mTc heart perfusion agent. Nucl. Med. Biol. 39, 207-213 (2012)
59. Meszaros, L. K., Dose, A., Biagini, S. C. G., Blower, P. J.: Synthesis and evaluation of analogues of HYNIC as bifunctional chelators for technetium. Dalton Trans. 40, 6260-6267 (2011)
60. Abiraj, K., Mansi, R., Tamma, M.-L., Forrer, F., Cescato, R., Reubi, J. C., Akyel, K. G., Maecke, H. R.: Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours. Chem. Eur. J. 16, 2115-2124 (2010)
61. Banerjee, S. R., Maresca, K. P., Stephenson, K. A., Valliant, J. F., Babich, J. W., Graham, W. A., Barzana, M., Dong, Q., Fischman, A. J., Zubieta, J.: N,N-Bis(2-mercaptoethyl)methylamine: A new coligand for Tc-99m labeling of hydrazinonicotinamide peptides. Bioconj. Chem. 16, 885-902 (2005)
62. Kim, Y.-S., He, Z., Hsieh,W.-Y. and Liu, S.: A novel ternary ligand system useful for preparation of cationic 99mTc-diazenido complexes and 99mTc-labeling of small biomolecules. Bioconj. Chem. 17, 473-484 (2006)
63. King, R., Surfraz,M. B.-U., Finucane, C., Biagini, S. C. G., Blower, P. J., Mather, S. J.: 99mTc-HYNIC-gastrin peptides: Assisted coordination of 99mTc by amino acid side chains results in improved performance both in vitro and in vivo. J. Nucl. Med. 50, 591-598 (2009)
64. Rose, D. J., Maresca, K. P., Nicholson, T., Davison, A., Jones, A. G., Babich, J., Fischman, A., Graham,W., DeBord, J. R. D., Zubieta, J.: Synthesis and characterization of organohydrazino complexes of technetium, rhenium, and molybdenum with the {M(η1-HxNNR)(η2-HyNNR)} core and their relationship to radiolabeled organohydrazine-derivatized chemotactic peptides with diagnostic applications. Inorg. Chem. 37, 2701-2716 (1998)
65. Cyr, J. E., Pearson, D. A., Wilson, D. M., Nelson, C. A., Guaraldi, M., Azure, M. T., Lister-James, J., Dinkelborg, L. M., Dean, R. T.: Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186: Chemistry and initial biological studies. J. Med. Chem. 50, 1354-1364 (2007)
66. Boschi, A., Bolzati, C., Benini, E., Malagò, E., Uccelli, L., Duatti, A., Piffanelli, A., Refosco, F., Tisato, F.: A novel approach to the high-specific-activity labeling of small peptides with the technetium-99m fragment [99mTc(N)(PXP)]2+ (PXP = Diphosphine Ligand). Bioconj. Chem. 12, 1035-1042 (2001)
67. Fernandes, C., Kniess, T., Gano, L., Seifert, S., Spies, H., Santos, I.: Synthesis and biological evaluation of silylated mixedligand 99mTc complexes with the [PNS/S] donor atom set. Nucl. Med. Biol., 31, 785-793 (2004)
68. Pietzsch, H.-J., Tisato, F., Refosco, F., Leibnitz, P., Drews, A., Seifert, S., Spies, H.: Synthesis and characterization of novel trig onal bipyramidal technetium(III) mixed-ligand complexes with SES/S/P coordination (E = O, N(CH3), S). Inorg. Chem. 40, 59-64 (2000)
69. Alberto, R., Schibli, R., Abram, U., Egli, A., Knapp, F. F., Schubiger, P. A.: Potential of the "[M(CO)3]+" (M = Re, Tc) moiety for the labeling of biomolecules. Radiochim. Acta 79, 99-103 (1997)
70. Alberto, R., Schibli, R., Egli, A., Schubiger, A. P., Herrmann, W. A., Artus, G., Abram, U., Kaden, T. A.: Metal carbonyl syntheses XXII. Low pressure carbonylation of [MOCl4]- and [MO4]-: the technetium(I) and rhenium(I) complexes [NEt4]2[MCl3(CO)3]. J. Organomet. Chem. 493, 119-127 (1995)
71. Alberto, R., Schibli, R., Egli, A., Schubiger, A. P., Abram, U., Kaden, T. A.: A novel organometallic aqua complex of technetium for the labeling of biomolecules:Synthesis of [99mTc(OH2)3(CO)3]+ from [99mTcO4]- in aqueous solution and its reaction with a bifunctional ligand. J. Am. Chem. Soc. 120, 7987-7988 (1998)
72. Alberto, R., Schibli, R., Schubiger, A. P., Abram, U., Pietzsch, H. J., Johannsen,B.: First application of fac-[99mTc(OH2)3(CO)3 ]+ in bioorganometallic chemistry: Design, structure, and in vitro affinity of a 5-HT(1A) receptor ligand labeled with 99mTc. J. Am. Chem. Soc. 121, 6076-6077 (1999)
73. Garcia, R., Paulo, A., Santos, I.: Rhenium and technetium complexes with anionic or neutral scorpionates: An overview of their relevance in biomedical applications. Inorg. Chim. Acta 362, 4315-4327 (2009)
74. Bowen, M. L., Lim, N. C., Ewart, C. B., Misri, R., Ferreira, C. L., Hafeli, U., Adam, M. J., Orvig, C.: Glucosamine conjugates bearing N,N,O-donors: potential imaging agents utilizing the [M(CO)3]+ core (M = Re, Tc). Dalton Trans. 9216-9227 (2009)
75. Mindt, T. L., Müller, C., Melis, M., de Jong, M., Schibli, R.: "Click-to-chelate": In vitro and in vivo comparison of a 99mTc(CO)3 -labeled N(t)-histidine folate derivative with its isostructural, clicked 1,2,3-triazole analogue. Bioconj. Chem. 19, 1689-1695 (2008)
76. Retzloff, L. B., Heinzke, L., Figureoa, S. D., Sublett, S. V., Ma, L., Sieckman, G. L., Rold, T. L., Santos, I., Hoffman, T. J., Smith, C. J.: Evaluation of [99mTc-(CO)3-X-Y-bombesin(7-14)NH2] conjugates for targeting gastrin-releasing peptide receptors overexpressed on breast carcinoma. Anticancer Res. 30, 19-30 (2010)
77. Taylor, A. T., Lipowska, M., Marzilli, L. G.: 99mTc(CO)3(NTA): A 99mTc renal tracer with pharmacokinetic properties comparable to those of 131I-OIH in healthy volunteers. J. Nucl. Med. 51, 391-396 (2010)
78. Tzanopoulou, S., Sagnou,M., Paravatou-petsotas, M., Gourni, E., Loudos, G., Xanthopoulos, S., Lafkas, D., Kiaris, H., Varvarigou, A., Pirmettis, I. C., Papadopoulos,M., Pelecanou,M.: Evaluation of Re and 99mTc complexes of 2-(4′-aminophenyl)benzothiazole as potential breast cancer radiopharmaceuticals. J. Med. Chem. 53, 4633-4641 (2010)
79. Vitor, R. F., Esteves, T., Marques, F., Raposinho, P., Paulo, A., Rodrigues, S., Rueff, J., Casimiro, S., Costa, L., Santos, I.: 99mTctricarbonyl complexes functionalized with anthracenyl fragments: Synthesis, characterization, and evaluation of their radiotoxic effects in murine melanoma cells. Cancer Biother. Radiopharm. 24, 551-563 (2009)
80. Struthers, H., Spingler, B., Mindt, T. L., Schibli, R.: "Click-to- Chelate": Design and incorporation of triazole-containing metalchelating systems into biomolecules of diagnostic and therapeutic interest. Chem. Eur. J. 14, 6173-6183 (2008)
81. Moore, A. L., Bucar, D.-K., MacGillivray, L. R., Benny, P. D.: "Click" labeling strategy for M(CO)3 (M = Re, 99mTc) prostate cancer targeted Flutamide agents. Dalton Trans. 39, 1926-1928 (2010)
82. Benny, P. D., Green, J. L., Engelbrecht, H. P., Barnes, C. L., Jurisson, S. S.: Reactivity of rhenium(V) oxo Schiff base complexes with phosphine ligands: Rearrangement and reduction reactions. Inorg. Chem. 44, 2381-2390 (2005)
83. Liu, G., Hnatowich, D. J.: Labeling biomolecules with radiorhenium - a review of the bifunctional chelators. Anti-Cancer Agents Med. Chem. 7, 367-377 (2007)
84. Liepe, K., Kotzerke, J.: A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl. Med. Commun. 28, 623-630 (2007)
85. Paes, F.M., Serafini,A. N.: Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin. Nucl. Med. 40, 89-104 (2010)
86. Syed, R., Bomanji, J. B., Nagabhushan,N., Kayani, I., Groves, A., Waddington,W., Cassoni, A., Ell, P. J.: 186Re-HEDP in the treatment of patients with inoperable osteosarcoma. J. Nucl. Med. 47, 1927-1935 (2006)
87. Zafeirakis, A.: Can response to palliative treatment with radiopharmaceuticals be further enhanced? Hellenic J. Nucl. Med. 12, 151-157 (2009)
88. Edelman, M. J., Clamon, G., Kahn, D., Magram, M., Lister-James, J., Line, B. R.: Targeted radiopharmaceutical therapy for advanced lung cancer: Phase 1 trial of rhenium Re188 P2045, a somatostatin analog. J. Thorac. Oncol. 4, 1550-1554 (2009)
89. Bernal, P., Raoul, J.-L., Stare, J., Sereegotov, E., Sundram, F. X., Kumar, A., Jeong, J.-M., Pusuwan, P., Divgi, C., Zanzonico, P., Vidmar, G., Buscombe, J., Chau, T. T. M., Saw, M. M., Chen, S., Ogbac, R., Dondi, M., Padhy, A. K.: International Atomic Energy Agency-sponsored multination study of intra-arterial rhenium- 188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: Results with special emphasis on prognostic value of dosimetric study. Semin. Nucl. Med. 38, S40-S45 (2008)
90. Cantorias,M. V., Howell, R. C., Todaro, L., Cyr, J. E., Berndorff, D., Rogers, R. D., Francesconi, L. C.: MO tripeptide diastereomers (M =99/99mTc, Re): Models to identify the structure of 99mTc peptide targeted radiopharmaceuticals. Inorg. Chem. 46, 7326-7340 (2007)
91. Schiller, E., Seifert, S., Tisato, F., Refosco, F., Kraus,W., Spies,H., Pietzsch, H.-J.: Mixed-ligand rhenium-188 complexes with tetradentate/ monodentate NS3/P (4′ +1′) coordination: Relation of structure with antioxidation stability. Bioconj. Chem. 16, 634-643 (2005)
92. Binkley, S. L., Barone, N. V., Underwood, A. C., Milsted, A., Franklin, B. R., Herrick, R. S., Ziegler, C. J.: The synthesis and toxicity of tripodal tricarbonyl rhenium complexes as radiopharmaceutical models. J. Inorg. Biochem. 104, 632-638 (2010)
93. Torres Martin De Rosales, R., Finucane, C., Foster, J., Mather, S. J., Blower, P. J.: 188Re(CO)3-dipicolylamine-alendronate:A new bisphosphonate conjugate for the radiotherapy of bone metastases. Bioconj. Chem. 21, 811-815 (2010)
94. Armstrong, A. F., Valliant, J. F.: Differences between the macroscopic and tracer level chemistry of rhenium and technetium: Contrasting cage isomerisation behaviour of Re(I) and Tc(I) carborane complexes. Dalton Trans. 39, 8128-8131 (2010)
95. Bonardi,M., Groppi, F., Manenti, S., Persico, E., Gini, L., Abbas, K., Holzwarth, U., Simonelli, F., Alfassi, Z.: Production study of high specific activity NCA Re-186g by proton and deuteron cyclotron irradiation. J. Radioanal. Nucl. Chem. 286, 1-7 (2010)
96. Lapi, S., Mills,W. J., Wilson, J., McQuarrie, S., Publicover, J., Schueller,M., Schyler, D., Ressler, J. J., Ruth, T. J.: Production cross-sections of 181-186Re isotopes from proton bombardment of natural tungsten. Appl. Radiat. Isotopes 65, 345-349 (2007)
97. Moustapha,M. E., Ehrhardt, G. J., Smith, C. J., Szajek, L. P., Eckelman, W. C., Jurisson, S. S.: Preparation of cyclotron-produced 186Re and comparison with reactor-produced 186Re and generatorproduced 188Re for the labeling of bombesin. Nucl. Med. Biol. 33, 81-89 (2006)
98. Szelecsényi, F., Steyn, G., Kovács, Z., Aardaneh, K., Vermeulen, C. and van derWalt, T.: Production possibility of 186Re via the 192Os(p, a3n) 186Re nuclear reaction. J. Radioanal. Nucl. Chem 282, 261-263 (2009)
99. Zhang, X., Li, Q., Li, W., Sheng, R., Shen, S.: Production of nocarrier- added 186Re via deuteron induced reactions on isotopically enriched 186W. Appl. Radiat. Isotopes 54, 89-92 (2001)
100. Anderson, C. J., Ferdani, R.: Copper-64 radiopharmaceuticals for PET imaging of cancer: Advances in preclinical and clinical research. Cancer Biother. Radiopharm. 24, 379-393 (2009)
101. Jones-Wilson, T. M., Deal, K. A., Anderson, C. J., McCarthy, D. W., Kovacs, Z., Motekaitis, R. J., Sherry, A. D., Martell, A. E., Welch, M. J.: The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nucl. Med. Biol. 25, 523-530 (1998)
102. Kukis, D. L., Diril, H., Greiner, D. P., DeNardo, S. J., DeNardo, G. L., Salako, Q. A., Meares, C. F.: A comparative study of copper-67 radiolabeling and kinetic stabilities of antibodymacrocyle chelate conjugates. Cancer 73, 779-786 (1994)
103. Motekaitis, R. J., Sun, Y., Martell, A. E., Welch,M. J.: Synthesis, characterization, and Cu(II) solution chemistry of dioxotetraazamacrocycles. Can. J. Chem. 77, 614-623 (1999)
104. Sun, X., Wuest,M., Kovacs, Z., Sherry, D., Motekaitis, R., Wang, Z., Martell, A., Welch, M., Anderson, C.: in vivo behavior of copper-64-labeled methanephosphonate tetraaza macrocyclic ligands. J. Biol. Inorg. Chem. 8, 217-225 (2003)
105. Sun, X., Wuest, M., Weisman, G. R., Wong, E. H., Reed, D. P., Boswell, C. A., Motekaitis, R., Martell, A. E., Welch, M. J., Anderson, C. J.: Radiolabeling and in vivo behavior of copper-64- labeled cross-bridged cyclam ligands. J. Med. Chem. 45, 469-477 (2001)
106. Boswell, C. A., Regino, C. A. S., Baidoo, K. E., Wong, K. J., Bumb, A., Xu, H., Milenic, D. E., Kelley, J. A., Lai, C. C., Brechbiel, M. W.: Synthesis of a cross-bridged cyclam derivative for peptide conjugation and 64Cu radiolabeling. Bioconj. Chem. 19, 1476-1484 (2008)
107. Hoffman, T. J., Smith, C. J.: True radiotracers: Cu-64 targeting vectors based upon bombesin peptide. Nucl. Med. Biol. 36, 579-585 (2009)
108. Liu, Z., Li, Z.-B., Cao, Q., Liu, S., Wang, F., Chen, X.: Smallanimal PET of tumors with 64Cu-labeled RGD-bombesin heterodimer. J. Nucl. Med. 50, 1168-1177 (2009)
109. Liu, Z., Yan, Y., Liu, S., Wang, F., Chen, X.: 18F, 64Cu, and 68Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconj. Chem. 20, 1016-1025 (2009)
110. Prasanphanich,A. F., Retzloff, L., Lane, S. R., Nanda, P. K., Sieckman,G. L., Rold, T. L., Ma, L., Figueroa, S. D., Sublett, S. V., Hoffman, T. J., Smith, C. J.: In vitro and in vivo analysis of [64Cu-NO2A-8-Aoc-BBN(7-14)NH2]: A site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors. Nucl. Med. Biol. 36, 171-181 (2009)
111. Yoshii, Y., Yoneda, M., Ikawa, M., Furukawa, T., Kiyono, Y., Mori, T., Yoshii, H., Oyama, N., Okazawa, H., Saga, T., Fujibayashi, Y.: Radiolabeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: studies with mitochondrial DNA-less ρ0 cells and cybrids carrying MELAS mitochondrial DNA mutation. Nucl. Med. Biol. 39, 177-185 (2012)
112. Good, S., Walter, M., Waser, B., Wang, X., Müller-Brand, J., Béhé,M., Reubi, J.-C., Maecke, H.: Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor- expressing tumours. Eur. J. Nucl. Med. Mol. Imag. 35, 1868-1877 (2008)
113. Motekaitis, R. J., Martell, A. E., Koch, S. A., Hwang, Quarless, D. A., Welch, M. J.: The gallium(III) and indium(III) complexes of tris(2- mercaptobenzyl)amine and tris(2-hydroxybenzyl)- amine. Inorg. Chem. 37, 5902-5911 (1998)
114. Bartholoma,M., Louie, A. S., Valliant, J., Zubieta, J.: Technetium and gallium derived radiopharmaceuticals: Comparing and contrasting the chemistry of two important radiometals for the molecular imaging era. Chem. Rev. 110, 2903-2920 (2010)
115. Heppeler, A., André, J. P., Buschmann, I., Wang, X., Reubi, J.-C., Hennig,M., Kaden, T. A., Maecke,H. R.: Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting. Chem. Eur. J. 14, 3026-3034 (2008)
116. Cutler, C. S., Smith, C. J., Ehrhardt, G. J., Tyler, T. T., Jurisson, S. S., Deutsch, E.: Current and potential therapeutic uses of lanthanide radioisotopes. Cancer Biother. Radiopharm. 15, 531- 545 (2000)
117. Jurisson, S. S., Cutler, C. S., Smith, S. V.: Radiometal complexes: characterization and relevant in vitro studies. Quart. J. Nucl. Med. Mol. Imag. 52, 222-234 (2008)
118. Li, W. P., Ma, D. S., Higginbotham, C., Hoffman, T., Ketring, A. R., Cutler, C. S., Jurisson, S. S.: Development of an in vitro model for assessing the in vivo stability of lanthanide chelates. Nucl. Med. Biol. 28, 145-154 (2001)
119. Aime, S., Botta, M., Fasano,M., Marques,M. P. M., Geraldes, C. F. G. C., Pubanz, D., Merbach, A. E.: Conformational and coordination equilibria on DOTA complexes of lanthanide metal ions in aqueous solution studied by 1H-NMR spectroscopy. Inorg. Chem. 36, 2059-2068 (1997)
120. Sun, Y., Martell, A. E., Reibenspies, J. H., Reichert, D. E., Welch, M. J.: Synthesis and characterization of racemic mixture and meso isomers of bis(trans-2-aminocyclohexyl)aminepentaacetic acid and the stabilities of their Gd(III) complexes. Inorg. Chem 39, 1480-1486 (2000)
121. Li,W. P., Smith, C. J., Cutler, C. S., Hoffman, T. J., Ketring, A. R., Jurisson, S. S.: Aminocarboxylate complexes and octreotide complexes with no carrier added 177Lu, 166Ho, and 149Pm. Nucl. Med. Biol. 30, 241-251 (2003)
122. Kobayashi, H., Wu, C., Yoo, T. M., Sun, B.-F., Drumm, D., Pastan, I., Paik, C. H., Gansow, O. A., Carrasquillo, J. A., Brechbiel, M. W.: Evaluation of the in vivo biodistribution of yttriumlabeled Isomers of CHX-DTPA-conjugated monoclonal antibodies. J. Nucl. Med. 39, 829-836 (1998)
123. Kozak, R. W., Raubitschek, A., Mirzadeh, S., Brechbiel,M. W., Junghaus, R., Gansow, O. A., Waldmann, T. A.: Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: Critical factors in determining in vivo survival and organ toxicity. Cancer Res. 49, 2639-2644 (1989)
124. McMurry, T. J., Pippin, C. G., Wu, C., Deal, K. A., Brechbiel, M.W., Mirzadeh, S., Gansow, O. A.: Physical parameters and biological stability of yttrium(III) diethylenetriaminepentaacetic acid derivative conjugates. J. Med. Chem. 41, 3546-3549 (1998)
125. Wu, C., Brechbiel,M. W., Gansow, O. A., Kobayashi, H., Carrasquillo, J. A., Pastan, I.: Stability of the four 2-(p-nitrobenzyl)- trans-CyDTPA 88Y complexes. Radiochim. Acta 79, 123-126 (1997)
126. Wu, C., Kobayashi, H., Sun, B., Yoo, T. M., Paik, C. H., Gansow, O. A., Carrasquillo, J. A., Pastan, I., Brechbiel,M. W.: Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(pnitrobenzyl)- trans-CyDTPA. Bioorg. Med. Chem. 5, 1925-1934 (1997)
127. Cheson, B. D.: Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101, 391-398 (2003)
128. Pysz,M. A., Gambhir, S. S., Willmann, J. K.: Molecular imaging: current status and emerging strategies. Clin. Radiol. 65, 500-516 (2010)
129. Brechbiel,M. W.: Targeted alpha-therapy: past, present, future? Dalton Trans. 4918-4928 (2007)
130. Mulford, D. A., Scheinberg, D. A., Jurcic, J. G.: The promise of targeted alpha-particle therapy. The J. Nucl. Med. 46, 199-204S (2005)
131. Zalutsky,M. R., Pozzi, O. R.: Radioimmunotherapy with alphaparticle emitting radionuclides. Quart. J. Nucl. Med. Mol. Imag 48, 289-296 (2004)
132. Song, H. A., Kang, C. S., Baidoo, K. E., Milenic, D. E., Chen, Y., Dai, A., Brechbiel,M. W., Chong, H.-S.: Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted α-radioimmunotherapy applications. Bioconj. Chem. 22, 1128-1135 (2011)
133. Holland, J. P., Williamson,M. J., Lewis, J. S.: Unconventional nuclides for radiopharmaceuticals.Mol. Imag. 9, 1-20 (2010)
134. Jurcic, J. G., Caron, P. C., Nikula, T. K., Papadopoulos, E. B., Finn, R. D., Gansow, O. A., Miller Jr., W. H., Geerlings,M. W., Warrell Jr., R. P., Larson, S. M., Scheinberg, D. A.: Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res. 55, 5908S-5910S (1995)
135. Wild, D., Frischknecht,M., Zhang, H., Morgenstern,A., Bruchertseifer, F., Boisclair, J., Provencher-Bolliger,A., Reubi, J.-C. and Maecke, H. R.: Alpha- vs. beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-pESIN and 213Bi- AMBA vs. 177Lu-DOTA-pESIN). Cancer Res. 71, 1009-1018 (2011)
136. Miederer,M., Scheinberg, D. A., McDevitt, M. R.: Realizing the potential of the actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv. Drug Deliv. Rev. 60, 1371-1382 (2008)
137. Couturier, O., Supiot, S., Degraef-Mougin,M., Faivre-Chauvet, A., Carlier, T., Chatal, J.-F., Davodeau, F., Cherel, M.: Cancer radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med. Mol. Imag. 32, 601-614 (2005)
138. Henriksen, G., Bruland, O. S., Larsen, R. H.: Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents. Anticancer Res. 24, 101-105 (2004)
139. Roesch, F., Riss, P. J.: The Renaissance of the 68Ge/68Ga radionuclide generator initiates new developments in 68Ga radiopharmaceutical chemistry. Curr. Top. Med. Chem. 10, 1633-1668 (2010)
140. Rösch, F., Baum, R. P.: Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS. Dalton Trans. 40, 6104-6111 (2011)
141. Berry, D. J., Ma, Y., Ballinger, J. R., Tavare, R., Koers, A., Sunassee, K., Zhou, T., Nawaz, S., Mullen, G. E. D., Hider, R. C., Blower, P. J.: Efficient bifunctional gallium-68 chelators for positron emission tomography: tris(hydroxypyridinone) ligands. Chem. Commun. 47, 7068-7070 (2011)
142. Notni, J., Šimecek, J., Hermann, P.,Wester,H.-J.: TRAP, a powerful and versatile framework for gallium-68 radiopharmaceuticals. Chem. Eur. J. 17, 14718-14722 (2011)
143. Rösch, F.: Radiolanthanides in endoradiotherapy: an overview. Radiochim. Acta 95, 303-311 (2007)
144. Holland, J. P., Sheh, Y., Lewis, J. S.: Standardized methods for the production of high specific-activity zirconium-89. Nucl. Med. Biol. 36, 729-739 (2009)
145. Holland, J. P., Divilov, V., Bander, N. H., Smith-Jones, P. M., Larson, S.M., Lewis, J. S.: 89Zr-DFO-J591 for ImmunoPET of prostate-specific membrane antigen expression in vivo. J. Nucl. Med. 51, 1293-1300 (2010)
146. Dijkers, E. C., Oude Munnink, T. H., Kosterink, J. G., Brouwers, A. H., Jager, P. L., De Jong, J. R., Van Dongen, G. A., Schröder, C. P., Lub-De Hooge, M. N., De Vries, E. G.: Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Therapeut 87, 586-592 (2010)
147. Holland, J. P., Caldas-Lopes, E., Divilov, V., Longo, V. A., Taldone, T., Zatorska, D., Chiosis, G., Lewis, J. S.: Measuring the pharmacodynamic effects of a novel HSP90 inhibitor on HER2/ neu expression in mice using 89Zr-DFO-trastuzumab. PLoS ONE 5, 1-11 (2010)
148. McCabe, K. E., Wu, A. M.: Positive progress in ImmunoPET - not just a coincidence. Cancer Biother. Radiopharm. 25, 253-261 (2007)
149. Tinianow, J. N., Gill, H. S., Ogasawara, A., Flores, J. E., Vanderbilt, A. N., Luis, E., Vandlen, R., Darwish, M., Junutula, J. R., Williams, S.-P. and Marik, J.: Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. Nucl. Med. Biol. 37, 289-297 (2010)
150. Bottenus, B. N., Kan, P., Jenkins, T., Ballard, B., Rold, T. L., Barnes, C., Cutler, C., Hoffman, T. J., Green,M. A., Jurisson, S. S.: Gold(III) bis-thiosemicarbazonato complexes: synthesis, characterization, radiochemistry and X-ray crystal structure analysis. Nucl. Med. Biol. 37, 41-49 (2010)
151. Chanda, N., Kan, P., Watkinson, L. D., Shukla, R., Zambre, A., Carmack, T. L., Engelbrecht, H., Lever, J. R., Katti, K., Fent, G. M., Casteel, S. W., Smith, C. J., Miller,W. H., Jurisson, S., Boote, E., Robertson, J. D., Cutler, C., Dobrovolskaia,M., Kannan, R., Katti, K. V.: Radioactive gold nanoparticles in cancer therapy: Therapeutic efficacy studies of GA-198AuNP nanoconstruct in prostate tumor-bearing mice. Nanomed. Nanotechnol. Biol. Med. 6, 201-209 (2010)
152. Kannan, R., Rahing, V., Cutler, C., Pandrapragada,R., Katti, K. K., Kattumuri, V., Robertson, J. D., Casteel, S. J., Jurisson, S., Smith, C., Boote, E., Katti, K. V.: Nanocompatible chemistry toward fabrication of target-specific gold nanoparticles. J. Am. Chem. Soc. 128, 11342-11343 (2006)
153. Katti, K. V., Kannan, R., Katti, K., Kattumori, V., Pandrapraganda, R.,
154. Helm, L., Merbach, A. E.: Applications of advanced experimental techniques: High pressure NMR and computer simulations. Dalton Trans. 633-641 (2002)
155. Rund, J. V., Basolo, F., Pearson, R. G.: Catalysis of substitution reactions of rhodium(III) complexes. The reaction of aquopentachlororhodate (III) ion with pyridine. Inorg. Chem. 3, 658-661 (1964)
156. Efe, G. E., Pillai,M. R. A., Schlemper, E. O., Troutner, D. E.: Rhodium complexes of two bidentate secondary amine oxime ligands and application to the labelling of proteins. Polyhedron 10, 1617-1624 (1991)
157. Lo, J. M., Pillai, M. R. A., John, C. S., Troutner, D. E.: Radiochemical purity evaluation of rhodium-105 complexes by magnesium oxide. Appl. Radiat. Isotopes 41, 103-105 (1990)
158. Goswami, N., 105Rh(III) complexes with acyclic tetrathioether ligands: Potential radiotherapeutic agents. Dissertation, University of Missouri (1996)
159. Goswami, N., Alberto, R., Barnes, C. L., Jurisson, S.: Rhodium (III) complexes with acyclic tetrathioether ligands. Effects of backbone chain length on the conformation of the Rh(III) complex. Inorg. Chem. 35, 7546-7555 (1996)
160. Goswami, N., Higginbotham, C., Volkert,W., Alberto, R., Nef, W., Jurisson, S.: Rhodium-105 tetrathioether complexes: radiochemistry and initial biological evaluation. Nucl. Med. Biol. 26, 951-957 (1999)
161. Jurisson, S. S., Ketring, A. R., Volkert,W. A.: Rhodium-105 complexes as potential radiotherapeutic agents. Trans. Metal Chem 22, 315-317 (1997)
162. Li, N., Struttman,M., Higginbotham, C., Grall, A. J., Skerlj, J. F., Vollano, J. F., Bridger, S. A., Ochrymowycz, L. A., Ketring, A. R., Abrams, M. J., Volkert,W. A.: Biodistribution of model 105Rhlabeled tetradentate thiamacrocycles in rats. Nucl. Med. Biol. 24, 85-92 (1997)
163. Venkatesh,M., Goswami, N., Volkert,W. A., Schlemper, E. O., Ketring, A. R., Barnes, C. L., Jurisson, S.: An Rh-105 complex of tetrathiacyclohexadecane diol with potential for formulating bifunctional chelates. Nucl. Med. Biol. 23, 33-40 (1996)
164. Akgun, Z., Synthesis and evaluation of 105Rhodium(III) complexes derived from diaminodithioether (DADTE) ligands. Dissertation, University of Missouri (2006)
165. Akgun, Z., Engelbrecht, H., Fan, K.-H., Barnes, C. L., Cutler, C. S., Jurisson, S. S., Lever, S. Z.: The complexation of rhodium(III) with acyclic diaminedithioether (DADTE) ligands. Dalton Trans. 39, 10169-10178 (2010)
166. Li, N.: Synthesis and characterization of rhodium-105-labeled thiamacrocycles for use to formulate peptide receptor agents. Dissertation, University of Missouri (1996)
167. Li, N., Eberlein, C.M., Volkert,W. A., Ochrymowycz, L., Barnes, C., Ketring, A. R.: Comparisons of 105Rh(III) chloride complexation with [14]aneNS3, [14]aneN2S2 and [14]aneN4 macrocycles in aqueous solution. Radiochim. Acta 75, 83-95 (1996)
168. Cagnolini,A., Ballard, B., Engelbrecht,H. P., Rold, T. L., Barnes, C., Cutler, C., Hoffman, T. J., Kannan, R., Katti, K., Jurisson, S. S.: Tetradentate bis-phosphine ligands (P2N2 and P2S2) and their Rh(III), Ni(II) and 105Rh complexes: X-ray crystal structures of trans-[RhCl2(L2)]PF6, [Ni(L2) ](PF6)2 and μ-O2SO2-[Ni(L5)]2- (PF6)2. Nucl. Med. Biol. 38, 63-76 (2011)
169. Jennings, L. E., Long, N. J.: "Two is better than one"-probes for dual-modality molecular imaging. Chem. Commun. 3511-3524 (2009)
170. Pascu, S. I., Waghorn, P. A., Conry, T., Lin, B., James, C., Zayed, J. M.: Design considerations towards simultaneously radiolabeled and fluorescent imaging probes incorporating metallic species. In: Advances in Inorganic Chemistry. (van Eldik, R., Hubbard, C. D., eds.) Academic Press, Oxford (2009), pp. 131- 178
171. Huang,W.-Y., Davis, J. J.: Multimodality and nanoparticles in medical imaging. Dalton Trans. 40, 6087-6103 (2011).